Visceral fat (VF) promotes the development of metabolic syndrome (MetS), which emerges as early as in adolescence. The clustering of MetS components suggests shared etiologies, but these are largely unknown and may vary between males and females. Here, we investigated the latent structure of pre-clinical MetS in a community-based sample of 286 male and 312 female adolescents, assessing their abdominal adiposity (VF) directly with magnetic resonance imaging. Principal component analysis of the five MetS-defining variables (VF, blood pressure [BP], fasting serum triglycerides, HDL-cholesterol and glucose) identified two independent components in both males and females. The first component was sex-similar; it explained >30% of variance and was loaded by all but BP variables. The second component explained >20% of variance; it was loaded by BP similarly in both sexes but additional loading by metabolic variables was sex-specific. This sex-specificity was not detected in analyses that used waist circumference instead of VF. In adolescence, MetS-defining variables cluster into at least two sub-syndromes: (1) sex-similar metabolic abnormalities of obesity-induced insulin resistance and (2) sex-specific metabolic abnormalities associated with BP elevation. These results suggest that the etiology of MetS may involve more than one pathway and that some of the pathways may differ between males and females. Further, the sex-specific metabolic abnormalities associated with BP elevation suggest the need for sex-specific prevention and treatment strategies of MetS.
References
[1]
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640–1645.
[2]
Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB (2005) Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112: 3066–3072.
[3]
Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, et al. (2003) Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108: 420–425.
[4]
Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Jama 287: 356–359.
[5]
Meigs JB, Wilson PW, Nathan DM, D'Agostino RB Sr, Williams K, et al. (2003) Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52: 2160–2167.
[6]
Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, et al. (2009) Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 119: 628–647.
[7]
Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH (2003) Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 157: 821–827.
[8]
Johnson WD, Kroon JJ, Greenway FL, Bouchard C, Ryan D, et al. (2009) Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001–2006. Arch Pediatr Adolesc Med 163: 371–377.
[9]
Prevalence of adolescent overweight and obesity in Canada in 1978/79 and 2004. Canadian Community Health Survey
[10]
Ogden CL, Flegal KM, Carroll MD, Johnson CL (2002) Prevalence and trends in overweight among US children and adolescents, 1999–2000. Jama 288: 1728–1732.
[11]
Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, et al. (2007) Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116: 39–48.
[12]
Demerath EW, Reed D, Rogers N, Sun SS, Lee M, et al. (2008) Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. Am J Clin Nutr 88: 1263–1271.
[13]
Smith JD, Borel AL, Nazare JA, Haffner SM, Balkau B, et al. (2012) Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study. J Clin Endocrinol Metab 97: 1517–1525.
[14]
Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, et al. (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168: 1617–1624.
[15]
Vega GL, Adams-Huet B, Peshock R, Willett D, Shah B, et al. (2006) Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab 91: 4459–4466.
[16]
Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, et al. (2005) Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension 45: 522–525.
[17]
Syme C, Abrahamowicz M, Leonard GT, Perron M, Pitiot A, et al. (2008) Intra-abdominal adiposity and individual components of the metabolic syndrome in adolescence: sex differences and underlying mechanisms. Arch Pediatr Adolesc Med 162: 453–461.
[18]
Pausova Z, Mahboubi A, Abrahamowicz M, Leonard GT, Perron M, et al. (2012) Sex differences in the contributions of visceral and total body fat to blood pressure in adolescence. Hypertension 59: 572–579.
[19]
McGill HC Jr, McMahan CA (2003) Starting earlier to prevent heart disease. Jama 290: 2320–2322.
[20]
Pausova Z, Paus T, Abrahamowicz M, Almerigi J, Arbour N, et al. (2007) Genes, maternal smoking, and the offspring brain and body during adolescence: design of the Saguenay Youth Study. Hum Brain Mapp 28: 502–518.
[21]
Cornier MA, Despres JP, Davis N, Grossniklaus DA, Klein S, et al. (2011) Assessing Adiposity: A Scientific Statement From the American Heart Association. Circulation 124: 1996–2019.
[22]
Brambilla P, Bedogni G, Moreno LA, Goran MI, Gutin B, et al. (2006) Crossvalidation of anthropometry against magnetic resonance imaging for the assessment of visceral and subcutaneous adipose tissue in children. Int J Obes (Lond) 30: 23–30.
[23]
Hu HH, Nayak KS, Goran MI (2011) Assessment of abdominal adipose tissue and organ fat content by magnetic resonance imaging. Obes Rev 12: e504–515.
[24]
Syme C, Abrahamowicz M, Leonard GT, Perron M, Richer L, et al. (2009) Sex differences in blood pressure and its relationship to body composition and metabolism in adolescence. Arch Pediatr Adolesc Med 163: 818–825.
[25]
Tanaka H, Thulesius O, Yamaguchi H, Mino M, Konishi K (1994) Continuous non-invasive finger blood pressure monitoring in children. Acta Paediatr 83: 646–652.
[26]
Paradis G, Lambert M, O'Loughlin J, Lavallee C, Aubin J, et al. (2004) Blood pressure and adiposity in children and adolescents. Circulation 110: 1832–1838.
[27]
Grebla RC, Rodriguez CJ, Borrell LN, Pickering TG (2010) Prevalence and determinants of isolated systolic hypertension among young adults: the 1999–2004 US National Health And Nutrition Examination Survey. J Hypertens 28: 15–23.
[28]
Griffith TF, Klassen PS, Franklin SS (2005) Systolic hypertension: an overview. Am Heart J 149: 769–775.
[29]
Fernandez JR, Redden DT, Pietrobelli A, Allison DB (2004) Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 145: 439–444.
[30]
Gillum RF, Prineas RJ, Horibe H (1982) Maturation vs age: assessing blood pressure by height. J Natl Med Assoc 74: 43–46.
[31]
Daniels SR, Kimball TR, Khoury P, Witt S, Morrison JA (1996) Correlates of the hemodynamic determinants of blood pressure. Hypertension 28: 37–41.
[32]
Jolliffe IT (2002) Principal component analysis. New York: Springer.
[33]
Woolston A, Tu YK, Baxter PD, Gilthorpe MS (2012) A comparison of different approaches to unravel the latent structure within metabolic syndrome. PLoS One 7: e34410.
[34]
Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595–1607.
[35]
Rosen ED, Spiegelman BM (2006) Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444: 847–853.
[36]
Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, et al. (2011) Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123: 2292–2333.
[37]
Kraja AT, Rao DC, Weder AB, Mosley TH, Turner ST, et al. (2005) An evaluation of the metabolic syndrome in a large multi-ethnic study: the Family Blood Pressure Program. Nutr Metab (Lond) 2: 17.
[38]
Kraja AT, Rao DC, Weder AB, Cooper R, Curb JD, et al. (2005) Two major QTLs and several others relate to factors of metabolic syndrome in the family blood pressure program. Hypertension 46: 751–757.
[39]
Mercuro G, Deidda M, Piras A, Dessalvi CC, Maffei S, et al. (2010) Gender determinants of cardiovascular risk factors and diseases. J Cardiovasc Med (Hagerstown) 11: 207–220.
[40]
Pimenta E, Oparil S (2008) Gender and blood pressure. In: Izzo JJ, Black H, Sica D, editors. Hypertension Primer. Philadelphia: Lippincott&Williams.
[41]
Biaggioni I (2008) Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension 51: 168–171.
Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58: 342–374.
Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1106–1118.
[51]
Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, et al. (2005) Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A 102: 9406–9411.
[52]
Guan Y, Hao C, Cha DR, Rao R, Lu W, et al. (2005) Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11: 861–866.
[53]
Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189–1195.
Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10: 355–361.
[56]
Rogol AD, Roemmich JN, Clark PA (2002) Growth at puberty. J Adolesc Health 31: 192–200.
[57]
Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM (1967) The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med 67: 48–59.
[58]
Freedman DS, Katzmarzyk PT, Dietz WH, Srinivasan SR, Berenson GS (2009) Relation of body mass index and skinfold thicknesses to cardiovascular disease risk factors in children: the Bogalusa Heart Study. Am J Clin Nutr 90: 210–216.
